M&A / Deals

Teva and Polpharma Biologics sign global deal for ocrelizumab biosimilar

Pharmaceutical Technology

Teva Pharmaceuticals International and Polpharma Biologics have signed a global licensing agreement for a proposed biosimilar to Ocrevus to treat multiple sclerosis.

Neuroscience

Read full story

pharminent July 10, 2026 (Last updated: July 10, 2026)

Pharmaceutical Technology

Teva Pharmaceuticals International and Polpharma Biologics have signed a global licensing agreement for a proposed biosimilar to Ocrevus to treat multiple sclerosis.

Neuroscience

Read full story

Related Stories

GSK ends dementia alliance with Alector after setbacks

AstraZeneca, GSK intensify China ties with Sino Biopharm deals

AstraZeneca bets up to $1.9B in respiratory disease collab with Sino Biopharmaceutical

You May Have Missed

Roche Scraps Two Ionis-Partnered Huntington’s Studies After Tominersen Failure

Hengrui-Kailera Oral GLP-1 Phase 3 Data Lands From China

AAIC 2026: Tau-targeted Alzheimer’s treatments heat up while amyloid therapies persist

Teva and Polpharma Biologics sign global deal for ocrelizumab biosimilar